Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer

被引:14
|
作者
Bonfanti, A
Lissoni, P [1 ]
Bucovec, R
Rovelli, F
Brivio, F
Fumagalli, L
机构
[1] Osped S Gerardo, Div Radioterapia Oncol, I-20052 Monza, MI, Italy
[2] Chiron Corp, Milan, Italy
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 2000年 / 15卷 / 02期
关键词
angiogenesis; dendritic cells; IL-2; IL-12; VEGF;
D O I
10.1177/172460080001500206
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Angiogenesis and immunosuppression are the main biological mechanisms responsible for cancer progression. Moreover, recent observations suggesting a negative influence of angiogenesis on anticancer immunity have shown that some angiogenic factors, such as VEGF, may induce immunosuppression. In addition, the evidence of abnormally high blood levels of VEGF has been proven to be associated with resistance to IL-2 immunotherapy. The present study was performed to establish a possible relation ship between the efficacy of IL-2 cancer immunotherapy and changes in circulating levels of VEGF, IL-12, mature and immature dendritic cells (DC). The study included 25 metastatic renal cell cancer patients who underwent subcutaneous low-dose IL-2 immunotherapy (6 MIU/day for 6 days/week for 4 weeks). Immature and mature DCs were identified as CD123+ and CD11c+ cells, respectively. The clinical response consisted of partial response (PR) in five, stable disease (SD) in 11 and progressive disease (PD) in the remaining nine patients. The mean IL-12 levels observed during IL-2 immunotherapy were significantly higher in patients with PR or SD than in those with PD, whereas the mean VEGF concentrations were significantly higher in patients who had PD than in those with PR or SD. Finally, a significant increase in the mean number of circulating mature DCs occurred only in patients with PR or SD, whereas no significant change was seen in patients with PD. By contrast, no significant change was observed in the mean number of immature DCs. This study shows that the efficacy of IL-2 immunotherapy is associated with a significant increase in circulating mature DCs and IL-12, without any concomitant increase in VEGF concentrations. Further studies will be required to better define the relationship between activation of anticancer immunity and control of angiogenesis-related mechanisms.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [21] Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin
    Lissoni, P
    Mandalà, M
    Brivio, F
    EUROPEAN UROLOGY, 2000, 38 (01) : 115 - 118
  • [22] IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer
    Gabrilovich, DI
    Cunningham, HT
    Carbone, DP
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (06): : 414 - 418
  • [23] Chicken γδ T cells proliferate upon IL-2 and IL-12 treatment and show a restricted receptor repertoire in cell culture
    Linti, Antonia E.
    Goebel, Thomas W.
    Frueh, Simon P.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells
    Zhang, Mengmeng
    Kong, Jingjing
    Yin, Fanxiang
    Shi, Jianxiang
    Li, Jin
    Qiu, Zan
    Yue, Baohong
    Wang, Shuya
    Sun, Nannan
    Lin, Quande
    Fu, Liyan
    Wang, Xiaoqian
    Sun, Xianlei
    Gao, Yanxia
    Jiang, Yong
    Guo, Rongqun
    CYTOKINE, 2024, 184
  • [25] Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes)
    Gratama, JW
    Schmitz, PIM
    Goey, SH
    Lamers, CHJ
    Stoter, G
    Bolhuis, RLH
    INTERNATIONAL JOURNAL OF CANCER, 1996, 65 (02) : 152 - 160
  • [26] High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
    Muhitch, Jason B.
    Schwaab, Thomas
    IMMUNOTHERAPY, 2014, 6 (09) : 955 - 958
  • [27] Standard interleukin-2 (IL-2) and interferon-α immunotherapy versus an IL-2 and 4-Epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma
    Naglieri, E
    Gebbia, V
    Durini, E
    Lelli, G
    Abbate, I
    Selvaggi, FP
    Di Tonno, P
    Colucci, G
    ANTICANCER RESEARCH, 1998, 18 (3B) : 2021 - 2026
  • [28] Expression of CXC chemokines during IL-2 therapy correlates with response in metastatic renal cell carcinoma
    Riedl, KL
    Figlin, RA
    Burdick, MD
    Strieter, RM
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S16 - S16
  • [29] IL-12 acid IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients
    Verma, V
    Sharma, V
    Shrivastava, SK
    Nadkarni, JJ
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2000, 19 (03) : 367 - 374
  • [30] A low-dose combination therapy of IL-2 and IFNα for metastatic renal cell cancer.
    Akaza, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 424S - 424S